domo.health Launches Generative AI to Transform Homecare by Reducing Administrative Burdens and Enhancing Collaboration
plus
Actualités de Lausanne -
Approach Switzerland is born, a pure-play cyber security and privacy firm
Lausanne (ots) - Approach, a Belgian pure-play cyber security and privacy company, established for more than 20 years, with clients and partners all around the world, is proud to announce the opening of a new branch in Switzerland. Approach's goal is to build a local team of about twenty Swiss colleagues within 2 years, establish strategic partnerships, and build ...
plusDEBIOPHARM SHARES ONCOLOGY PROGRAM UPDATES AT ASCO 2023 FOR NOVEL WEE1 INHIBITOR, AND FIRST-IN-CLASS CA IX THERANOSTIC APPROACH
Lausanne, Switzerland (ots) - - Debiopharm will highlight diversified approaches and commitment to improving outcomes for patients with cancer at the 2023 American Society of Clinical Oncology Conference - A poster presentation and discussion will cover promising interim results with Debio 0123, a potent, highly ...
plusDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
plusDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
plusDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
plusDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
plusIktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutions
Paris, France and Lausanne Switzerland (ots) - ● The round is co-led by M Ventures and Debiopharm Innovation Fund with Omnes Capital; all joining as new investors ● Series A will enable Iktos to expand its AI technology platform and launch Iktos Robotics; an AI-driven automated end-to-end drug discovery service ...
plusDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
plusDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots/PRNewswire) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a ...
plusDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
plusFEI Fédération Equestre Internationale
Belgium's Ingmar De Vos re-elected for third and final term as FEI President
Cape Town, South Africa and Lausanne, Switzerland (ots/PRNewswire) - Belgium's Ingmar De Vos has been re-elected with an overwhelming majority by the Fédération Equestre Internationale (FEI) member National Federations to serve a third and final term as FEI President. The Presidential election was held during today's FEI Hybrid General Assembly held in Cape Town ...
plusDebiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial Data
Boston, USA and Lausanne, Switzerland (ots) - - SaaS Platform Provides Missing Link in Clinical Trial Data Collection, Securely Automating Real-Time Transfer of Up-to-Date Patient Data Directly from EHRs to EDC Systems - Technology Brings New Levels of Speed, Quality and Efficiency to Clinical Trial Data Collection ...
plusScreeneo Innovation SA; Philipps
Philips Projection announces the Philips Screeneo U5.
Lausanne, Switzerland (ots/PRNewswire) - The Next Evolution in Ultra Short Throw 4K Laser Projection. Philips Projection is pleased to launch the Philips Screeneo U5, its Ultra Short Throw True 4K UHD Laser Projector that offers a 150" (381cm) breathtaking visual experiences from only 16.5 inches (42cm) away. In continuation to the success of the Screeneo U4 UST projector, the company brings the next evolution to the ...
plusDEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY
Lausanne, Switzerland (ots) - Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay ...
plusBIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY
Lausanne, Switzerland (ots) - · Currently approved Antibody-Drug Conjugates (ADCs) are large molecules (150 kDa) composed of an antibody, a cytotoxic payload, and a linker connecting the two precedent elements · Debiopharm has launched an ADC Innovation Challenge to a pool of international “problem Solvers” ...
plusDebiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical ...
plusDebiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Lausanne (ots) - Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm ...
plusONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS
Lausanne, Switzerland (ots) - - International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics - The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly ...
plusCompass Financial Technologies
COMPASS FINANCIAL TECHNOLOGIES AND MAREX TO COLLABORATE ON DIGITAL ASSET INVESTMENT SOLUTIONS
Lausanne, Switzerland and London (ots/PRNewswire) - Compass Financial Technologies, a Swiss and French based EU regulated index provider and Marex Solutions, Marex's hedging and investment solutions arm that specialises in customised derivative products, collaborate to offer digital asset investment solutions for institutional investors. Marex will leverage the ...
plusCredaris and Milenia join forces
plusSeries A financing round lays foundation for international growth of digital cancer therapeutics Mika
Berlin/Lausanne/Barcelona/Munich (ots) - New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika - an app-based DTx platform empowering people affected by cancer. Berlin-based digital health company Fosanis, the ...
plusDEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES
plusCompass Financial Technologies
COMPASS LAUNCHES FUNDAMENTAL DEFI INDEX AS INSTITUTIONAL DEMAND IN DIGITAL ASSETS CONTINUES TO SOAR
Lausanne, Switzerland (ots/PRNewswire) - Compass Financial Technologies, a leading crypto index provider that calculates indices that track over $5bn in assets announces the launch of the Compass Crypto Basket Fundamental DeFi Index (CCBFDEFI) - providing a reliable institutional benchmark to one of the fastest growing sectors in the crypto industry. The CCBFDEFI is ...
plusDEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA
Lausanne, Switzerland and Durban, South Africa (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar® (Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate ...
plusDEBIOPHARM IINVESTS IN VERISIM LIFE’S $15M SERIES A ROUND TO ADVANCE AI-ENABLED DRUG RESEARCH
Lausanne, Switzerland - San Francisco (ots) - Funding to support BIOiSIMTM computational platform to reduce the need for animal testing by selecting compounds showing promise to cure a disease prior to research in humans Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today their co-investment in California-based start-up VeriSIM Life’s ...
plusDEBIOPHARM FURTHER EXPLORES THE POTENTIAL OF ITS POTENT, HIGHLY SELECTIVE WEE1 INHIBITOR DEBIO 0123 IN PHASE 1 CANCER STUDY
Lausanne, Switzerland (ots) - Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly ...
plusSwiss-based Debiopharm co-invests in the future of cell therapies on a chip through the latest $25 million Series A round for Mekonos
Lausanne, Switzerland - San Francisco (ots) - Funding to accelerate the development of Mekonos’ System on a Chip (SoC), expand commercial partnerships Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today having invested $4M inMekonos, a biotech company building the future of cell ...
plusCARB-X FUNDS THE 3RD ROUND OF DEBIOPHARM’S TARGETED ANTIBIOTIC PROGRAM TO COMBAT RESISTANT N. GONORRHOEAE INFECTIONS
Lausanne, Switzerland / Boston, USA (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical ...
plusDEBIOPHARM & DEXA MEDICA LAUNCH TRIPTORELIN COLLABORATION TO BRING NEW HOPE TO WOMEN WITH ENDOMETRIOSIS
Lausanne, Switzerland – Tangerang, Indonesia (ots) - Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, today announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, ...
plus
123456Suivant